Monitoring chemotherapy-induced cardiotoxicity: Role of cardiac nuclear imaging

Journal of Nuclear Cardiology

Volumn 13, Issue 3, 2006, Pages 415-426

  Panjrath, Gurusher Singh ^a   Jain, Diwakar ^b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

apoptosis imaging; cardiomyopathy; diagnostic and prognostic application; MIBG imaging; radionuclide angiography

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ALPHA INTERFERON; ANTHRACYCLINE; ANTIOXIDANT; BEVACIZUMAB; BUSULFAN; CAPECITABINE; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; IDARUBICIN; IFOSFAMIDE; IMATINIB; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; PENTOSTATIN; RAZOXANE; RITUXIMAB; THALIDOMIDE; UNINDEXED DRUG; VINCA ALKALOID;

ACUTE DISEASE; ANGIOCARDIOGRAPHY; ANGIONEUROTIC EDEMA; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL DEATH; CHRONIC DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG DOSE REGIMEN; ECHOCARDIOGRAPHY; EDEMA; EXERCISE TEST; HEART ARRHYTHMIA; HEART INJURY; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART TAMPONADE; HEART VENTRICLE TACHYCARDIA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; HYPOTENSION; IMAGING SYSTEM; MONITORING; MORBIDITY; MORTALITY; MYOCARDITIS; NUCLEAR MEDICINE; PATHOGENESIS; PERICARDIAL EFFUSION; PERICARDITIS; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK FACTOR; SINUS BRADYCARDIA; SOLID TUMOR;

3-IODOBENZYLGUANIDINE; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; APOPTOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HEART DISEASES; HUMANS; MONITORING, PHYSIOLOGIC; MYOCARDIUM; NUCLEAR MEDICINE; PROGNOSIS; RADIONUCLIDE IMAGING; RISK; RISK FACTORS;

EID: 33646909432     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nuclcard.2006.03.002     Document Type: Review

References (104)

1. Yeh E.T., Tong A.T., Lenihan D.J., Yusuf S.W., Swafford J., Champion C., et al. Cardiovascular complications of cancer therapy. diagnosis, pathogenesis, and management. Circulation 109 (2004) 3122-3131
2. Meinardi M.T., Gietema J.A., van Veldhuisen D.J., van der Graaf W.T., de Vries E.G., and Sleijfer D.T. Long-term chemotherapy-related cardiovascular morbidity. Cancer Treat Rev 26 (2000) 429-447
3. Schultz P.N., Beck M.L., Stava C., and Vassilopoulou-Sellin R. Health profiles in 5836 long-term cancer survivors. Int J Cancer 104 (2003) 488-495
4. Hortobagyi G.N. Anthracyclines in the treatment of cancer. An overview. Drugs 54 Suppl 4 (1997) 1-7
5. Weiss R.B. The anthracyclines. will we ever find a better doxorubicin?. Semin Oncol 19 (1992) 670-686
6. Singal P.K., and Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 339 (1998) 900-905
7. Grenier M.A., and Lipshultz S.E. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 25 (1998) 72-85
8. Swain S.M., Whaley F.S., and Ewer M.S. Congestive heart failure in patients treated with doxorubicin. a retrospective analysis of three trials. Cancer 97 (2003) 2869-2879
9. Steinherz L.J., Steinherz P.G., Tan C.T., Heller G., and Murphy M.L. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266 (1991) 1672-1677
10. Postma A., Bink-Boelkens M.T., Beaufort-Krol G.C., Kengen R.A., Elzenga N.J., Schasfoort-van Leeuwen M.J., et al. Late cardiotoxicity after treatment for a malignant bone tumor. Med Pediatr Oncol 26 (1996) 230-237
11. Von Hoff D.D., Layard M.W., Basa P., Davis Jr. H.L., Von Hoff A.L., Rozencweig M., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91 (1979) 710-717
12. Lipshultz S.E., Giantris A.L., Lipsitz S.R., Kimball Dalton V., Asselin B.L., Barr R.D., et al. Doxorubicin administration by continuous infusion is not cardioprotective. the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 20 (2002) 1677-1682
13. Legha S.S., Benjamin R.S., Mackay B., Ewer M., Wallace S., Valdivieso M., et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96 (1982) 133-139
14. Lipshultz S.E., Lipsitz S.R., Mone S.M., Goorin A.M., Sallan S.E., Sanders S.P., et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332 (1995) 1738-1743
15. Krischer J.P., Epstein S., Cuthbertson D.D., Goorin A.M., Epstein M.L., and Lipshultz S.E. Clinical cardiotoxicity following anthracycline treatment for childhood cancer. the Pediatric Oncology Group experience. J Clin Oncol 15 (1997) 1544-1552
16. Kinsella T.J., Ahmann D.L., Giuliani E.R., and Lie J.T. Adriamycin cardiotoxicity in stage IV breast cancer. possible enhancement with prior left chest radiation therapy. Int J Radiat Oncol Biol Phys 5 (1979) 1997-2002
17. Gehl J., Boesgaard M., Paaske T., Vittrup Jensen B., and Dombernowsky P. Combined doxorubicin and paclitaxel in advanced breast cancer. effective and cardiotoxic. Ann Oncol 7 (1996) 687-693
18. Tan-Chiu E., Yothers G., Romond E., Geyer Jr. C.E., Ewer M., Keefe D., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer. NSABP B-31. J Clin Oncol 23 (2005) 7811-7819
19. Minow R.A., Benjamin R.S., Lee E.T., and Gottlieb J.A. Adriamycin cardiomyopathy-risk factors. Cancer 39 (1977) 1397-1402
20. Lipshultz S.E., Rifai N., Dalton V.M., Levy D.E., Silverman L.B., Lipsitz S.R., et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351 (2004) 145-153
21. de Graaf H., Dolsma W.V., Willemse P.H., van der Graaf W.T., Sleijfer D.T., de Vries E.G., et al. Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer. Br J Cancer 76 (1997) 943-945
22. Zhou S., Starkov A., Froberg M.K., Leino R.L., and Wallace K.B. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res 61 (2001) 771-777
23. Shadle S.E., Bammel B.P., Cusack B.J., Knighton R.A., Olson S.J., Mushlin P.S., et al. Daunorubicin cardiotoxicity. evidence for the importance of the quinone moiety in a free-radical-independent mechanism. Biochem Pharmacol 60 (2000) 1435-1444
24. Halili-Rutman I., Hershko C., Link G., Rutman A.J., and Shainberg A. Inhibition of calcium accumulation by the sarcoplasmic reticulum. a putative mechanism for the cardiotoxicity of adriamycin. Biochem Pharmacol 54 (1997) 211-214
25. Rajagopalan S., Politi P.M., Sinha B.K., and Myers C.E. Adriamycin-induced free radical formation in the perfused rat heart. implications for cardiotoxicity. Cancer Res 48 (1988) 4766-4769
26. Hershko C., Pinson A., and Link G. Prevention of anthracycline cardiotoxicity by iron chelation. Acta Haematol 95 (1996) 87-92
27. Panjrath G.S., Patel V., Narula N., Valdiviezo C.I., Narula J., and Jain D. Potentiation of doxorubicin cardiotoxicity by iron loading in a rodent model. [abstract]. J Am Coll Cardiol 45 (2005) 182A
28. Doroshow J.H., Locker G.Y., and Myers C.E. Enzymatic defenses of the mouse heart against reactive oxygen metabolites. alterations produced by doxorubicin. J Clin Invest 65 (1980) 128-135
29. Dorr R.T. Cytoprotective agents for anthracyclines. Semin Oncol 23 (1996) 23-34
30. Dragojevic-Simic V.M., Dobric S.L., Bokonjic D.R., Vucinic Z.M., Sinovec S.M., Jacevic V.M., et al. Amifostine protection against doxorubicin cardiotoxicity in rats. Anticancer Drugs 15 (2004) 169-178
31. Jahnukainen K., Jahnukainen T., Salmi T.T., Svechnikov K., Eksborg S., and Soder O. Amifostine protects against early but not late toxic effects of doxorubicin in infant rats. Cancer Res 61 (2001) 6423-6427
32. Villani F., Galimberti M., Monti E., Piccinini F., Lanza E., Rozza A., et al. Effect of glutathione and N-acetylcysteine on in vitro and in vivo cardiac toxicity of doxorubicin. Free Radic Res Commun 11 (1990) 145-151
33. Siveski-Iliskovic N., Hill M., Chow D.A., and Singal P.K. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 91 (1995) 10-15
34. Li T., and Singal P.K. Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation 102 (2000) 2105-2110
35. Kumar D., Kirshenbaum L.A., Li T., Danelisen I., and Singal P.K. Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxid Redox Signal 3 (2001) 135-145
36. Andrieu-Abadie N., Jaffrezou J.P., Hatem S., Laurent G., Levade T., and Mercadier J.J. L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes. role of inhibition of ceramide generation. FASEB J 13 (1999) 1501-1510
37. Hong Y.M., Kim H.S., and Yoon H.R. Serum lipid and fatty acid profiles in adriamycin-treated rats after administration of L-carnitine. Pediatr Res 51 (2002) 249-255
38. Kawasaki N., Lee J., Shimizu H., and Ueda T. Long-term 1-carnitine treatment prolongs the survival in rats with adriamycin-induced heart failure. J Card Fail 2 (1996) 293-299
39. Speyer J.L., Green M.D., Kramer E., Rey M., Sanger J., Ward C., et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319 (1988) 745-752
40. Hochster H.S. Clinical pharmacology of dexrazoxane. Semin Oncol 25 (1998) 37-42
41. Malisza K.L., and Hasinoff B.B. Inhibition of anthracycline semiquinone formation by ICRF-187 (dexrazoxane) in cells. Free Radic Biol Med 20 (1996) 905-914
42. Schuchter L.M., Hensley M.L., Meropol N.J., and Winer E.P. 2002 Update of recommendations for the use of chemotherapy and radiotherapy protectants. Clinical Practice Guidelines of the American Society of Clinical Oncology. J Clin Oncol 20 (2002) 2895-2903
43. Swain S.M., Whaley F.S., Gerber M.C., Weisberg S., York M., Spicer D., et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15 (1997) 1318-1332
44. Wexler L.H., Andrich M.P., Venzon D., Berg S.L., Weaver-McClure L., Chen C.C., et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 14 (1996) 362-372
45. van Dalen E.C., Caron H.N., Dickinson H.O., and Kremer L.C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev (2005) CD003917
46. Noori A., Lindenfeld J., Wolfel E., Ferguson D., Bristow M.R., and Lowes B.D. Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail 6 (2000) 115-119
47. Spallarossa P., Garibaldi S., Altieri P., Fabbi P., Manca V., Nasti S., et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 37 (2004) 837-846
48. Vaynblat M., Shah H.R., Bhaskaran D., Ramdev G., Davis III W.J., Cunningham Jr. J.N., et al. Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin. Eur J Heart Fail 4 (2002) 583-586
49. Valero V., Buzdar A.U., Theriault R.L., Azarnia N., Fonseca G.A., Willey J., et al. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol 17 (1999) 1425-1434
50. Berry G., Billingham M., Alderman E., Richardson P., Torti F., Lum B., et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 9 (1998) 711-716
51. Working P.K., Newman M.S., Sullivan T., and Yarrington J. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes. J Pharmacol Exp Ther 289 (1999) 1128-1133
52. Kanter P.M., Klaich G., Bullard G.A., King J.M., and Pavelic Z.P. Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99) given intraperitoneally to dogs. In Vivo 8 (1994) 975-982
53. Kanter P.M., Bullard G.A., Ginsberg R.A., Pilkiewicz F.G., Mayer L.D., Cullis P.R., et al. Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. In Vivo 7 (1993) 17-26
54. O'Brien M.E., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15 (2004) 440-449
55. Safra T., Muggia F., Jeffers S., Tsao-Wei D.D., Groshen S., Lyass O., et al. Pegylated liposomal doxorubicin (doxil). reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 11 (2000) 1029-1033
56. Gabizon A.A., Lyass O., Berry G.J., and Wildgust M. Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest 22 (2004) 663-669
57. Nair R., Ramakrishnan G., Nair N.N., Saikia T.K., Parikh P.M., Joshi S.R., et al. A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphoma. Cancer 82 (1998) 2282-2288
58. Nielsen O.S., Dombernowsky P., Mouridsen H., Crowther D., Verweij J., Buesa J., et al. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer 78 (1998) 1634-1639
59. Schrijvers D., Bos A.M., Dyck J., de Vries E.G., Wanders J., Roelvink M., et al. Phase I study of MEN-10755, a new anthracycline in patients with solid tumours. a report from the European Organization for Research and Treatment of Cancer, Early Clinical Studies Group. Ann Oncol 13 (2002) 385-391
60. Henderson I.C., Allegra J.C., Woodcock T., Wolff S., Bryan S., Cartwright K., et al. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7 (1989) 560-571
61. Caponigro F., Willemse P., Sorio R., Floquet A., van Belle S., Demol J., et al. A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer. Invest New Drugs 23 (2005) 85-89
62. Torti F.M., Bristow M.M., Lum B.L., Carter S.K., Howes A.E., Aston D.A., et al. Cardiotoxicity of epirubicin and doxorubicin. assessment by endomyocardial biopsy. Cancer Res 46 (1986) 3722-3727
63. Bristow M.R., Mason J.W., Billingham M.E., and Daniels J.R. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 102 (1981) 709-718
64. Druck M.N., Gulenchyn K.Y., Evans W.K., Gotlieb A., Srigley J.R., Bar-Shlomo B.Z., et al. Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity. Cancer 53 (1984) 1667-1674
65. Isner J.M., Ferrans V.J., Cohen S.R., Witkind B.G., Virmani R., Gottdiener J.S., et al. Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy. Am J Cardiol 51 (1983) 1167-1174
66. Piver M.S., Marchetti D.L., Parthasarathy K.L., Bakshi S., and Reese P. Doxorubicin hydrochloride (Adriamycin) cardiotoxicity evaluated by sequential radionuclide angiocardiography. Cancer 56 (1985) 76-80
67. Ritchie J.L., Singer J.W., Thorning D., Sorensen S.G., and Hamilton G.W. Anthracycline cardiotoxicity. clinical and pathologic outcomes assessed by radionuclide ejection fraction. Cancer 46 (1980) 1109-1116
68. Alexander J., Dainiak N., Berger H.J., Goldman L., Johnstone D., Reduto L., et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 300 (1979) 278-283
69. Choi B.W., Berger H.J., Schwartz P.E., Alexander J., Wackers F.J., Gottschalk A., et al. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance. Am Heart J 106 (1983) 638-643
70. Schwartz R., and Zaret B. Diagnosis and treatment of drug induced myocardial disease. In: Muggia F.C.S.J. (Ed). Cardiotoxicity of anticancer therapy. 1st ed. (1992), Johns Hopkins University Press, Baltimore 173-197
71. Schwartz R.G., McKenzie W.B., Alexander J., Sager P., D'Souza A., Manatunga A., et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 82 (1987) 1109-1118
72. Palmeri S.T., Bonow R.O., Myers C.E., Seipp C., Jenkins J., Green M.V., et al. Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. Am J Cardiol 58 (1986) 607-613
73. Gottdiener J.S., Mathisen D.J., Borer J.S., Bonow R.O., Myers C.E., Barr L.H., et al. Doxorubicin cardiotoxicity. assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med 94 (1981) 430-435
74. Gibbons R.J., Lee K.L., Cobb F., and Jones R.H. Ejection fraction response to exercise in patients with chest pain and normal coronary arteriograms. Circulation 64 (1981) 952-957
75. Stoddard M.F., Seeger J., Liddell N.E., Hadley T.J., Sullivan D.M., and Kupersmith J. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 20 (1992) 62-69
76. Schmitt K., Tulzer G., Merl M., Aichhorn G., Grillenberger A., Wiesinger G., et al. Early detection of doxorubicin and daunorubicin cardiotoxicity by echocardiography. diastolic versus systolic parameters. Eur J Pediatr 154 (1995) 201-204
77. Ganz W.I., Sridhar K.S., and Forness T.J. Detection of early anthracycline cardiotoxicity by monitoring the peak filling rate. Am J Clin Oncol 16 (1993) 109-112
78. Cottin Y., Touzery C., Coudert B., Gilles A., Walker P., Massing J.L., et al. Impairment of diastolic function during short-term anthracycline chemotherapy. Br Heart J 73 (1995) 61-64
79. Mitani I., Jain D., Joska T.M., Burtness B., and Zaret B.L. Doxorubicin cardiotoxicity. prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol 10 (2003) 132-139
80. Nousiainen T., Vanninen E., Jantunen E., Puustinen J., Remes J., Rantala A., et al. Comparison of echocardiography and radionuclide ventriculography in the follow-up of left ventricular systolic function in adult lymphoma patients during doxorubicin therapy. J Intern Med 249 (2001) 297-303
81. Wakasugi S., Fischman A.J., Babich J.W., Aretz H.T., Callahan R.J., Nakaki M., et al. Metaiodobenzylguanidine. evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy. J Nucl Med 34 (1993) 1283-1286
82. Wakasugi S., Wada A., Hasegawa Y., Nakano S., and Shibata N. Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine. J Nucl Med 33 (1992) 208-214
83. Carrio I., Estorch M., Berna L., Lopez-Pousa J., Tabernero J., and Torres G. Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med 36 (1995) 2044-2049
84. Lekakis J., Prassopoulos V., Athanassiadis P., Kostamis P., and Moulopoulos S. Doxorubicin-induced cardiac neurotoxicity. study with iodine 123-labeled metaiodobenzylguanidine scintigraphy. J Nucl Cardiol 3 (1996) 37-41
85. Takano H., Ozawa H., Kobayashi I., Hamaoka S., Nakajima J., Nakamura T., et al. Myocardial sympathetic dysinnervation in doxorubicin cardiomyopathy. J Cardiol 27 (1996) 49-55
86. Estorch M., Carrio I., Berna L., Martinez-Duncker C., Alonso C., Germa J.R., et al. Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. J Nucl Med 31 (1990) 1965-1969
87. Carrio I., Lopez-Pousa A., Estorch M., Duncker D., Berna L., Torres G., et al. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies. J Nucl Med 34 (1993) 1503-1507
88. Jain D., and Zaret B.L. Antimyosin cardiac imaging. will it play a role in the detection of doxorubicin cardiotoxicity?. J Nucl Med 31 (1990) 1970-1974
89. Narula J., Strauss H.W., and Khaw B.A. Antimyosin positivity in doxorubicin cardiotoxicity. earlier than the conventional evidence. J Nucl Med 34 (1993) 1507-1509
90. Maini C.L., Sciuto R., Ferraironi A., Vici P., Tofani A., Festa A., et al. Clinical relevance of radionuclide angiography and antimyosin immunoscintigraphy for risk assessment in epirubicin cardiotoxicity. J Nucl Cardiol 4 (1997) 502-508
91. Arola O.J., Saraste A., Pulkki K., Kallajoki M., Parvinen M., and Voipio-Pulkki L.M. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 60 (2000) 1789-1792
92. Nakamura T., Ueda Y., Juan Y., Katsuda S., Takahashi H., and Koh E. Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats. in vivo study. Circulation 102 (2000) 572-578
93. Bennink R.J., van den Hoff M.J., van Hemert F.J., de Bruin K.M., Spijkerboer A.L., Vanderheyden J.L., et al. Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats. J Nucl Med 45 (2004) 842-848
94. Panjrath G.S., Hartung D., Petrov A., Narula N., Patel V., Liu Z., et al. Increased Tc-99m-Annexin uptake in doxorubicin induced myocardial apoptosis. [abstract]. J Am Coll Cardiol 41 (2003) 444
95. Panjrath G.S., Patel V., Narula N., Narula J., and Jain D. Doxorubicin cardiotoxicity in a rodent model of iron overload. assessment using Tc-99m-annexin. [abstract]. J Nucl Cardiol 12 (2005) S14
96. Herman E.H., Zhang J., Lipshultz S.E., Rifai N., Chadwick D., Takeda K., et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 17 (1999) 2237-2243
97. Lipshultz S.E., Rifai N., Sallan S.E., Lipsitz S.R., Dalton V., Sacks D.B., et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 96 (1997) 2641-2648
98. Kismet E., Varan A., Ayabakan C., Alehan D., Portakal O., and Buyukpamukcu M. Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin. Pediatr Blood Cancer 42 (2004) 220-224
99. Mathew P., Suarez W., Kip K., Bayar E., Jasty R., Matloub Y., et al. Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? A pilot study. Cancer Invest 19 (2001) 352-359
100. Sparano J.A., Brown D.L., and Wolff A.C. Predicting cancer therapy-induced cardiotoxicity. the role of troponins and other markers. Drug Saf 25 (2002) 301-311
101. Nousiainen T., Jantunen E., Vanninen E., Remes J., Vuolteenaho O., and Hartikainen J. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur J Haematol 62 (1999) 135-141
102. Nousiainen T., Vanninen E., Jantunen E., Puustinen J., Remes J., Rantala A., et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med 251 (2002) 228-234
103. Suzuki T., Hayashi D., Yamazaki T., Mizuno T., Kanda Y., Komuro I., et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 136 (1998) 362-363
104. Valdes Olmos R.A., ten Bokkel Huinink W.W., ten Hoeve R.F., van Tinteren H., Bruning P.F., van Vlies B., et al. Assessment of anthracycline-related myocardial adrenergic derangement by [123i]metaiodobenzylguanidine scintigraphy. Eur J Cancer 31 (1995) 26-31